Healthcare Global Enterprises Ltd
NSE:HCG
Healthcare Global Enterprises Ltd
HealthCare Global Enterprises Ltd. provides imaging and diagnostics services for cancer treatment. The company is headquartered in Bangalore, Karnataka. The company went IPO on 2016-03-30. The firm is involved retail sale of pharmaceuticals, medical and orthopedic goods and toilet articles. The company operates cancer care network under the HCG brand. The company operates infertility treatment clinics providing assisted reproductive services under brand Milann. The firm operates eight Milann fertility centers, which provide reproductive medicine services, including assisted reproduction, gynecological endoscopy and fertility preservation; and follow a multidisciplinary and technology-focused approach to diagnosis and treatment. Milann fertility centers also offer training programs for fertility specialists and embryologists. Under the Triesta brand, it provides clinical reference laboratory services with specialization in oncology.
HealthCare Global Enterprises Ltd. provides imaging and diagnostics services for cancer treatment. The company is headquartered in Bangalore, Karnataka. The company went IPO on 2016-03-30. The firm is involved retail sale of pharmaceuticals, medical and orthopedic goods and toilet articles. The company operates cancer care network under the HCG brand. The company operates infertility treatment clinics providing assisted reproductive services under brand Milann. The firm operates eight Milann fertility centers, which provide reproductive medicine services, including assisted reproduction, gynecological endoscopy and fertility preservation; and follow a multidisciplinary and technology-focused approach to diagnosis and treatment. Milann fertility centers also offer training programs for fertility specialists and embryologists. Under the Triesta brand, it provides clinical reference laboratory services with specialization in oncology.
Revenue Growth: Q3 revenue rose 13.4% year-on-year to INR 633 crores, with 8% patient volume growth and stronger utilization despite a seasonally soft quarter.
Margin Expansion: Adjusted EBITDA grew 20% year-on-year to INR 111 crores, with margin improvement to 17.5%, driven by operating leverage and improved case mix.
Guidance Reiterated: Management maintained 15%+ annual revenue growth guidance, but expressed aspirations for even higher growth as capacity is added.
Cluster Performance: West and East clusters showed strong double-digit growth; South cluster was impacted by disruptions but recovered by quarter-end.
Digital Demand: Digital revenue climbed 26% YoY with improved conversion, higher app contribution, and reduced aggregator dependence.
ROCE and CapEx: 9M FY26 pre-tax ROCE was 13.3%, with a stated goal of 20% in 4–5 years; capex for FY26 expected at INR 275–280 crores.
Expansion Plans: Major bed additions planned via brownfield and greenfield projects, especially in Bangalore, with continued focus on operational ramp-up.
